Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.…
Mobia Medical to Participate in the Piper Sandler 38th Annual Healthcare Conference
Mobia Medical (NASDAQ: MOBI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 167 employees.
The shares were at 11.85 USD on 20 November 2026. Its 52-week range is 8.030 USD to 15.25 USD: the price is 22.3% below the high and 47.6% above the low.
Its market capitalisation is 394.50M USD.
Mobia Medical reports return on equity of 30.8%, an operating margin of -130.6% and revenue up 73.3% year over year.
It holds more cash than debt, a net cash position of 152.32M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 18.00 USD is 51.9% above the current price. The next earnings report is expected on 23 March 2027.